This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Labcorp Stock Gains From Its Latest Acquisition of BioReference Health
by Zacks Equity Research
LH completes the acquisition of BioReference Health, a wholly-owned subsidiary of OPKO Health. The acquisition includes BioReference Health's laboratory testing businesses.
QGEN Stock Likely to Gain From Innovation Amid Competition
by Zacks Equity Research
To support internal growth, QIAGEN invests heavily in research and development for the menu expansion of its key platforms.
DGX Stock Likely to Gain From Allina Health's Select Lab Assets Buyout
by Zacks Equity Research
With the completion of the acquisition, Allina Health's clinic physicians will now have access to Quest Diagnostics' laboratory services.
Should You Continue to Retain MYGN Stock in Your Portfolio?
by Zacks Equity Research
Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.
Zacks.com featured highlights include TransMedics, Iamgold, Graham and GIII Apparel
by Zacks Equity Research
TransMedics, Iamgold, Graham and GIII Apparel have been highlighted in this Screen of The Week article.
KIDS Stock Gains From Its New Enabling Technologies Division Launch
by Zacks Equity Research
OrthoPediatrics recently launched its Enabling Technologies division, set to generate sustainable revenue growth and gain access to new markets and specialties beyond orthopedics.
4 Stocks Backed by High Efficiency for Solid Gains Amid Volatility
by Santanu Roy
Invest in stocks of TMDX, IAG, GHM and GIII to tap their high-efficiency levels.
CVS Stock Gains From Its Birth Control Prescribing Service Launch
by Zacks Equity Research
CVS Health announces that nearly 400 CVS Pharmacy locations in Massachusetts have started offering hormonal contraceptive prescribing services.
Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes
by Zacks Equity Research
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
Sanara Stock Gains From New US Distribution Deal With ChemoMouthPiece
by Zacks Equity Research
SMTI, along with InfuSystem, inked a U.S. distribution agreement with ChemoMouthpiece. Under the agreement, ChemoMouthpiece's oral cryotherapy device will be distributed in cancer centers.
Should You Continue to Retain OMCL Stock in Your Portfolio Now?
by Zacks Equity Research
Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.
Paragon 28 Stock Gains From the Latest Launch of Its Right-Angle Drill
by Zacks Equity Research
FNA launched the Right-Angle Drill to enhance the APEX 3D Total Ankle Replacement System. The drill is designed to improve tibia preparation.
Reasons to Retain ResMed Stock in Your Portfolio for Now
by Zacks Equity Research
Strong demand for RMD's market-leading mask portfolio raises investors' optimism.
Will Trinity Biotech Stock Gain From Its Latest Patent Process?
by Zacks Equity Research
TRIB announces updates on its European patented process. The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology.
PBH Stock Might Get a Boost From Focused Brand-Building Efforts
by Zacks Equity Research
Prestige Consumer puts emphasis on brand building and product innovation in niche consumer healthcare categories to improve the lives of its consumers.
Can HITI Stock Get a Boost From Bricks-and-Mortar Sales in Q3 Earnings?
by Zacks Equity Research
Given High Tide's progress in executing its strategic initiatives, we expect it to report robust Q3 bricks-and-mortar segment sales.
Will Paragon 28 Stock Gain From the Latest Product Launch of R3FLEX?
by Zacks Equity Research
FNA recently introduced the R3FLEX Stabilization System, whose design should allow surgeons to restore a patient's soft tissue to a more natural anatomy.
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
by Zacks Equity Research
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
Align Technology Stock Dips on Macroeconomic Issues, FX Headwind
by Zacks Equity Research
ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This is resulting in a decline in the company's revenues.
Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?
by Zacks Equity Research
ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.
QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping
by Zacks Equity Research
QGEN collaborates with Eli Lilly to develop a QIAstat-Dx IVD panel for APOE genotyping.
Should You Continue to Retain ABT Stock in Your Portfolio Now?
by Zacks Equity Research
Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.
New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues
by Zacks Equity Research
MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.
Reasons to Retain STERIS Stock in Your Portfolio for Now
by Zacks Equity Research
STE's strong prospects in the healthcare business arm bode well for investors.
Zynex Stock Rises on FDA Clearance of Its New Pain Management Device
by Zacks Equity Research
ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.